Unfortunately, almost all patients will ultimately develop resistance to EGFR-TKI, in whom more than 50% cases were detected harboring the EGFR T790M mutation in tumor specimens after EGFR-TKI [6], [7]. This evidence concerns the gene EGFR and neoplasm.